+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID05885295

Understanding Cognitive Function After Stroke Using a New Digital Assessment Tool A Study of Brain Imaging, Blood Tests, and Cognitive Monitoring Over One Year

Led by Imperial College London · Updated on 2023-06-01

700

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Stroke is a major cause of death and long-term disability worldwide, often leading to ongoing cognitive problems that affect recovery and therapy engagement. There is no widely accepted gold standard for identifying cognitive deficits after stroke, and many clinical services lack resources for long-term cognitive monitoring. This research aims to develop and validate a digital cognitive screening tool called the Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease IC3 to detect both general and specific cognitive impairments in stroke survivors with minimal input from health professionals. The study also seeks to identify new brain imaging and blood biomarkers linked to cognitive recovery after stroke. The IC3 assessment includes 22 brief tasks covering various cognitive domains and several validated questionnaires, taking about 60-70 minutes to complete on any modern device via a web browser. This tool is designed to be scalable, cost-effective, and usable both in clinical settings and at home, making it accessible for patients with physical disabilities. The study is a prospective observational trial recruiting 300 stroke patients and age-matched healthy controls, with repeated cognitive and psychosocial assessments at baseline, 3, 6, and 12 months. Additional sub-studies include brain MRI scans and blood biomarker sampling at multiple time points to explore links to cognitive outcomes. Participants will complete cognitive tasks and questionnaires remotely or in clinic, with results compared to normative data from healthy controls. Brain imaging and blood samples will be collected to assess structural and biochemical markers related to stroke recovery. The main outcome measured is cognition one year after stroke, alongside other functional and neurological scales. Safety and eligibility will be carefully monitored, and participants can contribute to understanding how best to detect and track cognitive changes post-stroke over time.

CONDITIONS

Brief Title

The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here